NIAGX | RSEBX | NIAGX / RSEBX | |
Total Expense Ratio | 0.98 | 1.45 | 68% |
Annual Report Gross Expense Ratio | 1.38 | 1.45 | 95% |
Fund Existence | 3 years | 11 years | - |
Gain YTD | 13.487 | 9.389 | 144% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 1000 | 250 | 400% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 85.2M | 80.3B | 0% |
Annual Yield % from dividends | 0.53 | 0.23 | 226% |
Returns for 1 year | 14.52 | 9.79 | 148% |
Returns for 3 years | 26.02 | 20.18 | 129% |
Returns for 5 years | N/A | 12.50 | - |
Returns for 10 years | N/A | 44.85 | - |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
PHPSX | 21.80 | 0.16 | +0.74% |
ProFunds Pharmaceuticals UltraSector Svc | |||
FRIFX | 12.20 | 0.01 | +0.08% |
Fidelity Real Estate Income | |||
JNVYX | 19.07 | -0.01 | -0.05% |
Jensen Quality Mid Cap Y | |||
VALIX | 14.35 | -0.01 | -0.07% |
Value Line Capital Appreciation Investor | |||
QCSCX | 22.01 | -0.04 | -0.18% |
Federated Hermes MDT Small Cap Core C |